BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Sickle cell disease clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for sickle cell disease: 42 (25 sponsors; 2 newly posted in the last 180 days, 3 stopped in the last 180 days; 1 new-entrant sponsors). Momentum score 15.5, rank 42 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 3, Phase 2 13, Phase 3 15, Phase 4 2, N/A 8.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VERX | 3 | P3 3 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 5 | P4 1, P1 1, P2 1, P3 2 | 0 | 0 |
| Agios Pharmaceuticals, Inc. AGIO | 4 | P4 1, P3 2, P2 1 | 1 | 0 |
| Novo Nordisk A/S NVO | 2 | P3 2 | 0 | 0 |
| Sanofi SNY | 2 | P3 2 | 0 | 1 |
| Forma Therapeutics, Inc. | 3 | P2 2, P3 1 | 0 | 0 |
| Genetix Biotherapeutics Inc. | 2 | NA 1, P3 1 | 0 | 1 |
| Asklepion Pharmaceuticals, LLC | 1 | P3 1 | 0 | 0 |
| Pfizer PFE | 1 | P3 1 | 0 | 0 |
| Beam Therapeutics Inc. BEAM | 2 | P2 1, NA 1 | 0 | 0 |
| CSL Behring | 2 | P2 2 | 0 | 0 |
| Editas Medicine, Inc. EDIT | 2 | NA 1, P2 1 | 0 | 0 |
| Axiom Bioregistry new entrant | 1 | NA 1 | 1 | 0 |
| Biossil Inc. | 1 | P2 1 | 0 | 0 |
| Bristol-Myers Squibb BMY | 1 | P2 1 | 0 | 1 |
| CorrectSequence Therapeutics Co., Ltd | 1 | EARLY_P1 1 | 0 | 1 |
| Disc Medicine, Inc IRON | 1 | P1 1 | 0 | 0 |
| EpiDestiny, Inc. | 1 | P1 1 | 0 | 0 |
| Hemanext | 1 | NA 1 | 0 | 0 |
| Imara, Inc. | 1 | P2 1 | 0 | 0 |
| Kamau Therapeutics | 1 | P2 1 | 0 | 1 |
| Nova Laboratories Limited NVMI | 1 | NA 1 | 0 | 0 |
| Ossium Health, Inc. | 1 | NA 1 | 0 | 0 |
| Sangamo Therapeutics SGMOQ | 1 | NA 1 | 0 | 0 |
| Theravia | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: Axiom Bioregistry.
Recently stopped trials
- NCT07401823 Fulcrum Therapeutics - terminated: Sponsor Decision Open-Label Extension Study to Pioneer Study 6058-SCD-101
- NCT07155031 Cerus Corporation - withdrawn: This study has been suspended due to a lack of funding. The protocol will be reconsidered within the next 6-12 months if/as funding becomes Biotin-Acridine Red Cell Exchange Kinetics
- NCT07431398 Fulcrum Therapeutics - terminated: Sponsor decision Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-31 est. | P1/P2 | Kamau Therapeutics | NCT04819841 Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease | Sickle Cell Disease | recruiting | 15 |
| 2027-01-06 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT06481306 A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease | Anemia, Sickle Cell; Healthy Volunteers | recruiting | 224 |
| 2027-01-07 est. | P3 | Sanofi SNY | NCT07247188 Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | Sickle Cell Disease | recruiting | 100 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-09-30 | PDUFA date (company-disclosed) | date passed | AGIOS PHARMACEUTICALS, INC. AGIO | PDUFA September 30, 2026 - AGIOS PHARMACEUTICALS, INC. |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-30 est. | P2 | Cerus Corporation CERS | NCT07155031 Biotin-Acridine Red Cell Exchange Kinetics | Sickle Cell Disease | withdrawn | |
| 2026-06-30 | P2 | Hillhurst Biopharmaceuticals, Inc. | NCT06144749 A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) | Anemia, Sickle Cell | completed | 13 |
| 2026-06-04 | P2 | Fulcrum Therapeutics FULC | NCT07401823 Open-Label Extension Study to Pioneer Study 6058-SCD-101 | Sickle Cell Disease | terminated | 1 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "sickle cell disease"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.